Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Multiple Myeloma 3Leukemia, Myeloid, Acute 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Thrombocythemia, Essential 1Sezary Syndrome 1Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Rhabdomyosarcoma 1Recurrence 1Pseudomyxoma Peritonei 1Primary Myelofibrosis 1Precancerous Conditions 1Polycythemia Vera 1Pdgfra-Associated Chronic Eosinophilic Leukemia 1Neurofibrosarcoma 1Neurofibromatosis 1 1Neoplasms, Plasma Cell 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Mycosis Fungoides 1Multi-centric Castleman's Disease 1Macular dystrophy, corneal type 1 1

Interventions

Magnetic Resonance Spectroscopy 2tazemetostat 1selinexor 1pazopanib 1fludarabine phosphate 1fludarabine 1Specimen Handling 1Sirolimus 1Proton Therapy 1Nivolumab 1Mesna 1Ipilimumab 1Ifosfamide 1Doxorubicin 1Cyclophosphamide 1CTLA-4 Antigen 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neurofibrosarcoma × Sirolimus × 30 days × Clear all
NCT03433183 2026-05-27

SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors

Sarcoma Alliance for Research through Collaboration

Phase 2 Completed
21 enrolled 12 charts
CNSSarcoma

Neurofibromatosis 1, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡